{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:23:37Z","timestamp":1791116617828,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006378","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000}}],"reference-count":165,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006378.pub2","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T19:52:58Z","timestamp":1328903578000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease"],"prefix":"10.1002","volume":"2012","author":[{"given":"Darin","family":"Jaturapatporn","sequence":"first","affiliation":[{"name":"Mahidol University, Bangkok and Baycrest Centre for Geriatric Care, University of Toronto; Department of Family Medicine, Ramathibodi Hospital; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokhtar Gad El Kareem Nasr","family":"Isaac","sequence":"additional","affiliation":[{"name":"Sussex Partnership NHS Foundation Trust; Old Age Psychiatry; Master's House Compton Place Road Eastbourne East Sussex UK BN20 8BJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"McCleery","sequence":"additional","affiliation":[{"name":"University of Oxford; Cochrane Dementia and Cognitive Improvement Group; John Radcliffe Hospital Level 4, Main Hospital, Room 4401c Oxford Oxfordshire UK OX39DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Tabet","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School & Cognitive Treatment and Research Unit, Sussex Partnership NHS Foundation Trust; Institute of Postgraduate Medicine; Falmer Brighton UK BN1 9PH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006378.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","article-title":"Randomized pilot study of nimesulide treatment in Alzheimer's disease","volume":"58","author":"Aisen","year":"2002","journal-title":"Neurology"},{"issue":"21","key":"10.1002\/14651858.CD006378.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","article-title":"Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial","volume":"7","author":"Bentham","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"e1475","DOI":"10.1371\/journal.pone.0001475","article-title":"No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial","volume":"3","author":"Jong","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0006|cit6","unstructured":"H\u00fcll M Bauer J Treatment with the non-steroidal anti-inflammatory drug piroxicam-B-cyclodextrin in Alzheimer's disease Ninth Congress of the International Psychogeriatric Association, August 15-20, 1999, Vancouver Convention & Exhibition Centre Vancouver, British Columbia, Canada 1999 107"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1081\/CRP-120030034","article-title":"A Pharmacokinetic, Pharmacodynamic, and Safety Study of Celecoxib in Subjects with Probable Alzheimer\u2019s Disease","volume":"21","author":"Jhee","year":"2004","journal-title":"Clinical Research and Regulatory Affairs"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clinical & Experimental Research"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib - no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006378.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimers disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer's disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096588","article-title":"Long-term efficacy and safety of celecoxib in Alzheimer's disease","volume":"23","author":"Soininen","year":"2007","journal-title":"Dementia\u00a0and\u00a0Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0013|cit13","first-page":"1214","article-title":"Effectiveness of polydrug therapy for senile dementia","volume":"8","author":"Zhou","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0014|cit14","first-page":"3020","article-title":"Curative effect of aspirin for postponing the development of Alzheimer's disease","volume":"8","author":"Zhou","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"7","key":"10.1002\/14651858.CD006378.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Results of a randomized, controlled trial of naproxen and celecoxib","volume":"65","author":"Cognitive function over time in the Alzheimer's Disease Anti-Inflammatory Prevention trial (ADAPT)","year":"2008","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0016|cit16","first-page":"201","article-title":"A pilot study of prednisone in Alzheimer's disease","volume":"7","author":"Aisen","year":"1996","journal-title":"Dementia"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1034\/j.1600-0404.2000.00312.x","article-title":"Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial","volume":"102","author":"Aisen","year":"2000","journal-title":"Acta Neurologica Scandinavica Supplement"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD006378.pub2-BIB0019|cit19","first-page":"S35","article-title":"Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease","volume":"23","author":"Aisen","year":"2002","journal-title":"Journal of Pain\u00a0and\u00a0Symptom Management"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0306-4530(02)00015-X","article-title":"Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition","volume":"28","author":"Aisen","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/156720508783884602","article-title":"Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial","volume":"5","author":"Aisen","year":"2008","journal-title":"Current Alzheimer Research"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/156720508783884602","article-title":"Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial","volume":"5","author":"Aisen","year":"2008","journal-title":"Current Alzheimer Research"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0023|cit23","first-page":"78","article-title":"Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia","volume":"7","author":"Aizen","year":"2005","journal-title":"The Israel\u00a0Medical Association\u00a0Journal"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hup.838","article-title":"Treatment of the mild cognitive impairment (MCI)","volume":"22","author":"Allain","year":"2007","journal-title":"Human Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006378.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.54.11.2066","article-title":"Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study","volume":"54","author":"Anthony","year":"2000","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006378.pub2-BIB0026|cit26","first-page":"S11","article-title":"Alzheimer disease: current therapy and future therapeutic strategies","volume":"14","author":"Anthony","year":"2000","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00002093-199904000-00008","article-title":"Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease","volume":"13","author":"Asthana","year":"1999","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/jcp.0b013e318160862c","article-title":"Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease","volume":"28","author":"Baum","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0029|cit29","unstructured":"Beck K The safety and efficacy of an Investigational Drug (VIOXX) in Delaying the progression of Alzheimer's Disease ClinicalTrials.gov 2000 NCT00006187"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12031-002-0033-3","article-title":"Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone","volume":"19","author":"Belanoff","year":"2002","journal-title":"Journal of Molecular Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.59.6.880","article-title":"Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County study","volume":"59","author":"Belanoff","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1530\/eje.0.1420466","article-title":"Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia","volume":"142","author":"Bernardi","year":"2000","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0167-4943(96)00709-1","article-title":"Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in non-demented elderly patients admitted to a Geriatric Evaluation and Rehabilitation Unit","volume":"23","author":"Bertozzi","year":"1996","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0034|cit34","first-page":"A347","article-title":"Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study","volume":"66","author":"Black","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006378.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0197-4580(95)00049-K","article-title":"Delayed onset of Alzheimers disease with non-steroidal anti-inflammatory and histamine (H2) blocking drugs","volume":"16","author":"Breitner","year":"1995","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0036|cit36","unstructured":"Breitner J Randomized controlled trial of two non-steroidal anti-inflammatory drugs for prevention of Alzheimer's disease 39th Annual Meeting of the American College of Neuropsychopharmacology 2000"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Breitner JCS Haneuse SJPA Walker R Dublin S Crane PK Gray SL Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort Neurology 2009 1899 905","DOI":"10.1212\/WNL.0b013e3181a18691"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0038|cit38","first-page":"481","article-title":"Cognitive performance after cardiac operation: implications of regression toward the mean","volume":"117","author":"Browne","year":"1999","journal-title":"Journal of\u00a0Thoracic\u00a0and\u00a0Cardiovascular Surgery"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2125.1994.tb04320.x","article-title":"Indomethacin and cognitive function in healthy elderly volunteers","volume":"38","author":"Bruce-Jones","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1364.037","article-title":"Effect of high-dose cortisol on memory functions","volume":"1071","author":"Brunner","year":"2006","journal-title":"Annals of the\u00a0New York Academy\u00a0of Sciences"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0041|cit41","unstructured":"Budge M A pilot study for the VITAL trial (Vitamins and Aspirin for the Treatment of Dementia) National Research Register 2000"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1212\/WNL.62.6.1030","article-title":"DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Bullock","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD006378.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/j.1532-5415.2005.53572.x","article-title":"Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia","volume":"53","author":"Bussiere","year":"2005","journal-title":"Journal of the American Geriatrics Society"},{"issue":"16","key":"10.1002\/14651858.CD006378.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis","volume":"117","author":"Canigueral","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/156720505774932287","article-title":"A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type","volume":"2","author":"Chang","year":"2005","journal-title":"Current Alzheimer Research"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.2003.01154.x","article-title":"Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia","volume":"254","author":"Clarke","year":"2003","journal-title":"Journal of Internal Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006378.pub2-BIB0047|cit47","first-page":"1S8","article-title":"Ginkgo biloba extract (EGb 761) a state of art at the dawn of the year 2000","volume":"57","author":"Clostre","year":"1999","journal-title":"Annales Pharmaceutiques Francaises"},{"issue":"5-6","key":"10.1002\/14651858.CD006378.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","article-title":"Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The prevention regimen for effectively avoiding second strokes trial (PRoFESS)","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovascular Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006378.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","article-title":"Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006378.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1212\/WNL.46.4.1194","article-title":"NSAIDs and cognition in Alzheimer's disease","volume":"46","author":"Doraiswamy","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0051|cit51","unstructured":"Fisk J AD2000, a reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease National Research Register 2000"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0404.1989.tb04876.x","article-title":"Early stages of late onset Alzheimer's disease III Double blind treatment with choline chloride and lecithin with and without L-dopa and L-tryptophan, alternatively placebo","volume":"79","author":"Forssell","year":"1989","journal-title":"Acta Neurologica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jalz.2008.01.004","article-title":"Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study","volume":"4","author":"Fotuhi","year":"2008","journal-title":"Alzheimer's and Dementia"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0197-4580(04)80709-7","article-title":"Pioglitazone In Alzheimer's disease: rationale and clinical trial design","volume":"25","author":"Geldmacher","year":"2004","journal-title":"NeuroBiology of Aging"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","article-title":"A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study","volume":"22","author":"Gomez-Isla","year":"2008","journal-title":"Alzheimer Disease & Associated Disorders"},{"issue":"23","key":"10.1002\/14651858.CD006378.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"issue":"21","key":"10.1002\/14651858.CD006378.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0006-3223(87)90049-7","article-title":"RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects","volume":"22","author":"Hollander","year":"1987","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.wad.0000155067.16313.5e","article-title":"Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study","volume":"19","author":"Jackson","year":"2005","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjopharm.2009.06.002","article-title":"Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and\/or early-stage dementia: a single-center, retrospective, observational study","volume":"7","author":"Jacobs","year":"2009","journal-title":"American Journal of Geriatric Pharmacotherapy"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0061|cit61","unstructured":"Jacoby RJ A pilot study for the VITAL trial (Vitamins and Aspirin for the treatment of Dementia) National Research Register 2002"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S589","DOI":"10.1016\/S0197-4580(04)81961-4","article-title":"Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease","volume":"25","author":"Jeong","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200822010-00001","article-title":"The role of peroxisome proliferator-activated receptor- (PPAR) in Alzheimer's disease: therapeutic implications","volume":"22","author":"Jiang","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pbb.2008.01.016","article-title":"Dexibuprofen (s(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion","volume":"89","author":"Jin","year":"2008","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2008.04.020","article-title":"Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents","volume":"59","author":"Kimball","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00019442-200303000-00008","article-title":"Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients","volume":"11","author":"Landi","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006378.pub2-BIB0067|cit67","first-page":"S7","article-title":"Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study","volume":"54","author":"Laughlin","year":"2006","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Leblhuber F Haller H Steiner K Fuchs D DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial Neurology 2004 1030","DOI":"10.1212\/WNL.62.6.1030"},{"issue":"33","key":"10.1002\/14651858.CD006378.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.2174\/138161206778793029","article-title":"Selective modulation of A beta 42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond","volume":"12","author":"Leuchtenberger","year":"2006","journal-title":"Current Pharmaceutical Design"},{"issue":"12","key":"10.1002\/14651858.CD006378.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/0006-3223(94)90598-3","article-title":"Nonsteroidal antiinflammatory drug use in Alzheimer's disease","volume":"36","author":"Lucca","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006378.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pctr.0010033","article-title":"Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT)","volume":"1","author":"Martin","year":"2006","journal-title":"PLoS Clinical Trials"},{"issue":"7","key":"10.1002\/14651858.CD006378.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib","volume":"65","author":"Martin","year":"2008","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0073|cit73","first-page":"22","article-title":"MPC-7869 - prostate cancer therapy - treatment of Alzheimer's dementia","volume":"31","author":"McIntyre","year":"2006","journal-title":"Drugs of the Future"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","article-title":"Alzheimer's disease anti-inflammatory prevention trial: design, methods, and baseline results","volume":"5","author":"Meinert","year":"2009","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0075|cit75","first-page":"13","article-title":"Triflusal versus aspirin for the prevention of stroke","volume":"3","author":"Meinert","year":"2008","journal-title":"Progress in Neurotherapeutics and Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0076|cit76","first-page":"549","article-title":"Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study","volume":"37","author":"Meyer","year":"1989","journal-title":"Journal\u00a0of the American Geriatrics\u00a0Society"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0077|cit77","unstructured":"Meyer JS Chowdhury MH Quach M Randomized clinical trial of daily aspirin therapy in multi-infarct dementia 2nd International Congress on Vascular dementia, January, Salzburg, Austria, 2002 2002"},{"issue":"7","key":"10.1002\/14651858.CD006378.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0011-393X(02)80050-9","article-title":"An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia","volume":"63","author":"Nawata","year":"2002","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0079|cit79","first-page":"25","article-title":"Non steroidal anti-inflammatory drugs in Alzheimer disease","volume":"27","author":"Nourhashemi","year":"1998","journal-title":"Presse Medicale"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1542\/peds.2007-0486","article-title":"Followup of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: Neurodevelopmental outcomes at 4 to 11 years of age","volume":"120","author":"O'Shea","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000067428","article-title":"Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease","volume":"11","author":"Pasinetti","year":"2002","journal-title":"Neurosignals"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0082|cit82","unstructured":"Pfizer [Sponsor] A double-blind, randomized, placebo-controlled, comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease http:\/\/www.clinicalstudyresults.org\/documents\/company-study_76_0.pdf 2004"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0083|cit83","unstructured":"Pfizer [Sponsor] A placebo-controlled evaluation of the long-term efficacy and safety of celecoxib (SC-58635) In Alzheimer\u2019s disease http:\/\/www.clinicalstudyresults.org\/documents\/company-study_76_1.pdf 2005"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0197-4580(85)90055-7","article-title":"Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease","volume":"6","author":"Pomara","year":"1985","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11064-006-9055-5","article-title":"The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease","volume":"31","author":"Pomara","year":"2006","journal-title":"Neurochemical Research"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2005.00989.x","article-title":"A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence","volume":"100","author":"Reid","year":"2005","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000069988","article-title":"A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease","volume":"16","author":"Relkin","year":"2003","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0088|cit88","unstructured":"Sainati SM Ingram DM Talwalker S Geis GS Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 180"},{"issue":"9","key":"10.1002\/14651858.CD006378.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0090|cit90","unstructured":"Small GW Anti-inflammatory treatment for age-associated memory impairment: a double-blind placebo-controlled trial Alzheimer's Disease Education and Referral Center (ADEAR) 1999"},{"issue":"12","key":"10.1002\/14651858.CD006378.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/JGP.0b013e31818cd3a4","article-title":"Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study","volume":"16","author":"Small","year":"2008","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"16","key":"10.1002\/14651858.CD006378.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis","volume":"117","author":"Solomon","year":"2008","journal-title":"Circulation"},{"issue":"3B","key":"10.1002\/14651858.CD006378.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1590\/S0004-282X2008000500003","article-title":"Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer's disease","volume":"66","author":"Souza-Talarico","year":"2008","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0196-9781(91)90051-P","article-title":"Effects of an ACTH\/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans","volume":"12","author":"Steiger","year":"1991","journal-title":"Peptides"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1081\/CRP-120030034","article-title":"A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease","volume":"21","author":"Stevenson","year":"2004","journal-title":"Clinical Research and Regulatory Affairs"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.48.3.626","article-title":"Risk of Alzheimer's disease and duration of NSAID use","volume":"48","author":"Stewart","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006378.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-2007-979562","article-title":"Prescribing practice with cognition enhancers in outpatient care: Are there differences regarding type of dementia? Results of a representation survey in lower Saxony, Germany","volume":"29","author":"Stoppe","year":"1996","journal-title":"Pharmacopsychiatry"},{"issue":"24","key":"10.1002\/14651858.CD006378.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/01.wnl.0000313933.17796.f6","article-title":"No advantage of A beta(42)-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187152710791012026","article-title":"Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence","volume":"9","author":"Szekely","year":"2010","journal-title":"CNS and Neurological Disorders - Drug Targets"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0100|cit100","unstructured":"Taylor D 52 week double-blind, randomised, placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimers disease National Research Register 1999"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/187152711794488629","article-title":"Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs","volume":"10","author":"Tsartsalis","year":"2011","journal-title":"CNS & Neurological Disorders-Drug Targets"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","article-title":"The role of inflammation in Alzheimer's disease","volume":"37","author":"Tuppo","year":"2005","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.53.082901.103952","article-title":"Cyclooxygenase-2: a therapeutic target","volume":"53","author":"Turini","year":"2002","journal-title":"Annual Review of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1507\/endocrj.53.7","article-title":"Pharmaceutical prospects of phytoestrogens","volume":"53","author":"Usui","year":"2006","journal-title":"Endocrine Journal"},{"issue":"11","key":"10.1002\/14651858.CD006378.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/01.WNL.0000163804.94163.91","article-title":"Reversible impaired memory induced by pulsed methylprednisolone in patients with MS","volume":"64","author":"Uttner","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0306-4530(01)00014-2","article-title":"Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation","volume":"26","author":"Niekerk","year":"2001","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0108|cit108","first-page":"413","article-title":"The prediction and prevention of Alzheimer's disease - towards a research agenda","volume":"24","author":"Reekum","year":"1999","journal-title":"Journal of Psychiatry & Neuroscience"},{"issue":"10","key":"10.1002\/14651858.CD006378.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/jnnp.2004.047720","article-title":"Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?","volume":"76","author":"Visser","year":"2005","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"19","key":"10.1002\/14651858.CD006378.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of Alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"issue":"23","key":"10.1002\/14651858.CD006378.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2146\/ajhp050116","article-title":"Medication use as a risk factor for falls among hospitalized elderly patients","volume":"62","author":"Walker","year":"2005","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0b013e31820e861c","article-title":"Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia","volume":"31","author":"Walther","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0197-4580(04)80284-7","article-title":"Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease","volume":"25","author":"Watson","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002093-199812000-00007","article-title":"Clinical trial designs for demonstrating disease course altering effects in dementia","volume":"12","author":"Whitehouse","year":"1998","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"12","key":"10.1002\/14651858.CD006378.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","article-title":"Clopidogrel pre-treatment in stable angina: for all patients > 6 H before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial Prague-8","volume":"29","author":"Widimsky","year":"2008","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0116|cit116","unstructured":"Wilcock GK A pilot study for a large simple randomised trial to assess the effects of aspirin, anti-oxidant vitamins (C & E) and folic acid and Vitamin B12 in patients with dementia National Research Register 1999"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0117|cit117","unstructured":"Wilcock GK MPC-7869 effect on cognitive function in Alzheimer's National Research Register 2004"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jalz.2006.03.013","article-title":"Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with r-flurbiprofen","volume":"2","author":"Wilcock","year":"2006","journal-title":"Alzheimer's and Dementia"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006378.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11906-004-0026-4","article-title":"Protection against stroke and dementia: an update on the latest clinical trial evidence","volume":"6","author":"Williams","year":"2004","journal-title":"Current Hypertension Reports"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0121|cit121","first-page":"301","article-title":"Approach towards an integrative drug treatment of Alzheimer's disease","volume":"59","author":"Windisch","year":"2000","journal-title":"Journal of Neural Transmission, Supplement"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x","article-title":"Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group","volume":"94","author":"Wisloff","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.WNL.0000052994.54660.58","article-title":"DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study","volume":"60","author":"Wolkowitz","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006378.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/rheumatology\/39.9.935","article-title":"Selective Cox-2 inhibition in man - therapeutic breakthrough or cosmetic advance?","volume":"39","author":"Wollheim","year":"2000","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD006378.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1474-4422(02)00133-3","article-title":"The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease","volume":"1","author":"Woodward","year":"2002","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1542\/peds.2007-0486","article-title":"Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age","volume":"120","author":"Xia","year":"2007","journal-title":"Pediatrics"},{"issue":"9","key":"10.1002\/14651858.CD006378.pub2-BIB0127|cit127","first-page":"671","article-title":"New horizons in management of Alzheimer's disease","volume":"20","author":"Yaqub","year":"1999","journal-title":"Saudi Medical Journal"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2318-5-2","article-title":"Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study","volume":"5","author":"Yip","year":"2005","journal-title":"BMC Geriatriatrics"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Young AH Sahakian BJ Robbins TW Cowen PJ The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers Psychopharmacology 1999 260 6","DOI":"10.1007\/s002130051057"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0130|cit130","first-page":"200","article-title":"Pharmacological strategies for prevention of Alzheimer's disease: the epidemiologic evidence","volume":"10","author":"Zandi","year":"2005","journal-title":"Research and Practice in Alzheimer's Disease"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0131|cit131","first-page":"6","article-title":"Attitude before COX-2 selective inhibitors","volume":"57","author":"Zaragoza","year":"2005","journal-title":"Revista De Investigacion Clinica"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0132|cit132","doi-asserted-by":"crossref","unstructured":"Zerovnik E Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy Current Alzheimer Research 2010 74 83","DOI":"10.2174\/156720510790274437"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0133|cit133","first-page":"73","article-title":"Efficacy observation of batroxobin for treatment of vascular cognitive impairment","volume":"7","author":"Zhai","year":"2010","journal-title":"Chinese Journal of Cerebrovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nurt.2009.10.016","article-title":"Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury","volume":"7","author":"Ziebell","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1176\/ajp.151.8.1105","article-title":"Inflammatory mechanisms in Alzheimer's disease: Implications for therapy","volume":"151","author":"Aisen","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0136|cit136","first-page":"201","article-title":"A pilot study of prednisone in Alzheimer's disease","volume":"7","author":"\u00a0Aisen","year":"1996","journal-title":"Dementia"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-199812010-00001","article-title":"Glucocorticoids in Alzheimer's disease: the story so far","volume":"12","author":"Aisen","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0138|cit138","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1995"},{"issue":"35","key":"10.1002\/14651858.CD006378.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"31466","DOI":"10.1074\/jbc.M201308200","article-title":"Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein","volume":"277","author":"Avramovich","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0140|cit140","first-page":"S400","article-title":"Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease","volume":"50","author":"Bazan","year":"2009","journal-title":"Journal of\u00a0Lipid Research"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1006\/nbdi.2001.0451","article-title":"Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells","volume":"8","author":"Blasko","year":"Dec 2001","journal-title":"Neurobiology\u00a0of Disease"},{"issue":"6405","key":"10.1002\/14651858.CD006378.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/360672a0","article-title":"Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production","volume":"360","author":"Citron","year":"1992","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","article-title":"Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies\u00a0","volume":"327","author":"Etminan","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006378.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1471-4159.1997.68020704.x","article-title":"Prostaglandin E2 Induces Interleukin-6 Synthesis in Human Astrocytoma cells","volume":"68","author":"Fiebich","year":"1997","journal-title":"Journal of Neurochemistry"},{"issue":"26","key":"10.1002\/14651858.CD006378.pub2-BIB0146|cit146","first-page":"17741","article-title":"Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor","volume":"269","author":"Haass","year":"1994","journal-title":"Journal of Biological\u00a0Chemistry"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0968-4328(02)00029-X","article-title":"In vitro fibrillogenesis of the amyloid B1-42 peptide: cholesterol potentiation and aspirin inhibition","volume":"33","author":"Harris","year":"2002","journal-title":"Micron"},{"issue":"8","key":"10.1002\/14651858.CD006378.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","article-title":"Alzheimer disease in the US population: prevalence estimates using the 2000 census","volume":"60","author":"Hebert","year":"2003","journal-title":"Archives of\u00a0Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0149|cit149","first-page":"295","article-title":"Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease","volume":"57","author":"Ho","year":"1999","journal-title":"Journal\u00a0of\u00a0Neuroscience Research"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease","volume":"345","author":"In't","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006378.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00002093-199205000-00003","article-title":"The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease","volume":"6","author":"Joachim","year":"1992","journal-title":"Alzheimer Disease\u00a0& Associated\u00a0Disorders"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.51.3.728","article-title":"The incidence of dementia: a meta-analysis","volume":"51","author":"Jorm","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1017\/S0317167100029863","article-title":"Immune system response in Alzheimer's disease","volume":"16","author":"Mcgeer","year":"1989","journal-title":"Canadian Journal Neurological Sciences"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1212\/WNL.47.2.425","article-title":"Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies","volume":"47(2)","author":"McGeer","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0306-4522(98)00218-8","article-title":"Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain","volume":"87","author":"Pasinetti","year":"1998","journal-title":"Neuroscience"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.45.1.51","article-title":"Nonsteroidal anti-inflammatory drugs in Alzheimer's disease","volume":"45","author":"Rich","year":"1995","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006378.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2174\/156720509790147070","article-title":"Amyloid deposition and inflammation in APPswe\/PS1dE9 mouse model of Alzheimer's disease","volume":"6","author":"Ruan","year":"2009","journal-title":"Current Alzheimer\u00a0Research"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pneurobio.2009.01.001","article-title":"Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors","volume":"87","author":"Salminen","year":"2009","journal-title":"Progress in\u00a0Neurobiology"},{"issue":"6353","key":"10.1002\/14651858.CD006378.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/354432a0","article-title":"Alzheimer's disease. In the beginning","volume":"354","author":"Selkoe","year":"1991","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1097\/00001756-200110290-00024","article-title":"Aspirin and non-steroidal anti-inflammatory drug inhibit amyloid-B aggregation","volume":"12","author":"Thomas","year":"2001","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0162|cit162","volume-title":"The ICD-10 Classification of Mental and Behavioural disorders: clinical Descriptions and Diagnostic Guidelines","author":"World Health Organisation","year":"1992"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0163|cit163","first-page":"S81","article-title":"Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in Alzheimers disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.","volume":"2","author":"Wilcock","year":"2006","journal-title":"Alzheimer and Dementia"},{"key":"10.1002\/14651858.CD006378.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jalz.2007.02.001","article-title":"An estimate of the total worldwide societal costs of dementia in 2005","volume":"3","author":"Wimo","year":"2007","journal-title":"Alzheimer's & dementia"},{"issue":"3","key":"10.1002\/14651858.CD006378.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.410370303","article-title":"Evidence that A beta 42 is the real culprit in Alzheimer's disease","volume":"37","author":"Younkin","year":"1995","journal-title":"Annals of Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006378.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:17:32Z","timestamp":1747653452000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006378.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":165,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006378.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}